Sodium-glucose cotransporter2 inhibitors: A drug with antidiabetic and cardioprotective properties.

Abstract

Recently, two large double-blind randomized controlled trials testing the effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with heart failure with and without diabetes have led to a paradigm shift for the indication of this class of drugs. Key clinical features and main results in these two studies are summarized in Table 1 and 2. The dapagliflozin and prevention of adverse outcomes in heart failure (DAPA-HF) trial included 4744 patients with heart failure and a reduced ejection fraction (HFrEF).